Kirsten Bibbins-Domingo, Glenn M. Chertow, Pamela G. Coxson, Arthur Moran, James M. Lightwood, Mark J. Pletcher, Lee Goldman
9 min
This study aimed to quantify the potential public health and economic benefits of achieving population-wide reductions in dietary salt intake in the United States. Given that the majority of salt in the American diet originates from processed foods, the researchers evaluated whether a regulatory approach to lowering salt intake could serve as an effective strategy for reducing cardiovascular disease (CVD) and associated healthcare expenditures.
Researchers utilized the Coronary Heart Disease (CHD) Policy Model, a computer-simulation, state-transition model of heart disease incidence, prevalence, mortality, and costs among U.S. adults aged 35 and older. The model was used to simulate the effects of reducing daily salt intake by up to 3 grams per day. The team estimated the impact across various demographic subgroups—stratified by age, sex, and race—and compared these projections against other established public health interventions, such as smoking cessation, obesity reduction, and the use of statins or antihypertensive medications.
The analysis projects that a 3-gram-per-day reduction in salt would result in 60,000 to 120,000 fewer new CHD cases, 32,000 to 66,000 fewer strokes, and 44,000 to 92,000 fewer deaths annually. These benefits are expected to be widespread, with black populations, women, and older adults seeing particularly significant improvements in health outcomes. Furthermore, the study found that such an intervention would be cost-saving, generating between 24 billion in annual healthcare savings. Even a more modest, gradual reduction of 1 gram per day was found to be cost-effective, outperforming the cost-effectiveness of treating all hypertensive individuals with medication alone.
These findings suggest that population-wide salt reduction is a highly efficient public health strategy that could rival the impact of other major cardiovascular prevention efforts. By shifting the focus from individual clinical management to regulatory measures—such as salt limits in processed foods—policymakers could achieve substantial improvements in national health outcomes while simultaneously reducing the economic burden on the healthcare system.
BACKGROUND: The U.S. diet is high in salt, with the majority coming from processed foods. Reducing dietary salt is a potentially important target for the improvement of public health. METHODS: We used the Coronary Heart Disease (CHD) Policy Model to quantify the benefits of potentially achievable, population-wide reductions in dietary salt of up to 3 g per day (1200 mg of sodium per day). We estimated the rates and costs of cardiovascular disease in subgroups defined by age, sex, and race; compared the effects of salt reduction with those of other interventions intended to reduce the risk of cardiovascular disease; and determined the cost-effectiveness of salt reduction as compared with the treatment of hypertension with medications. RESULTS: Reducing dietary salt by 3 g per day is projected to reduce the annual number of new cases of CHD by 60,000 to 120,000, stroke by 32,000 to 66,000, and myocardial infarction by 54,000 to 99,000 and to reduce the annual number of deaths from any cause by 44,000 to 92,000. All segments of the population would benefit, with blacks benefiting proportionately more, women benefiting particularly from stroke reduction, older adults from reductions in CHD events, and younger adults from lower mortality rates. The cardiovascular benefits of reduced salt intake are on par with the benefits of population-wide reductions in tobacco use, obesity, and cholesterol levels. A regulatory intervention designed to achieve a reduction in salt intake of 3 g per day would save 194,000 to 392,000 quality-adjusted life-years and $10 billion to $24 billion in health care costs annually. Such an intervention would be cost-saving even if only a modest reduction of 1 g per day were achieved gradually between 2010 and 2019 and would be more cost-effective than using medications to lower blood pressure in all persons with hypertension. CONCLUSIONS: Modest reductions in dietary salt could substantially reduce cardiovascular events and medical costs and should be a public health target.
Alex: Those factors establish the starting population. Where does the dietary change enter?
Sam: Through systolic blood pressure, the pressure when the heart contracts. The authors use published evidence to estimate how much that pressure falls when salt intake falls. The model then translates the lower pressure into changes in disease and mortality.
Alex: That translation sounds decisive. Do they assume everyone’s blood pressure responds equally?
Sam: No. They model stronger responses among black adults, older adults, and people with hypertension, meaning persistently high blood pressure. They also run lower and higher estimates of the blood-pressure response, based on a meta-analysis and clinical trial evidence.
Alex: Give us the main result, with its comparison. How large is the projected difference from leaving consumption unchanged?
Sam: The main salt-reduction scenario projects sixty thousand to one hundred twenty thousand fewer new coronary heart disease cases annually. That’s compared with current salt consumption in the model. Coronary heart disease affects the vessels supplying the heart.
Alex: That’s disease incidence, not just a laboratory measurement. Does the model also project a difference in survival?
Sam: It projects forty-four thousand to ninety-two thousand fewer deaths from any cause each year. It also projects fewer strokes and fewer new and recurrent heart attacks. These outcomes overlap, so their counts shouldn’t be added together as separate people helped.
Alex: How should we hear those ranges? Are they uncertainty bounds around one estimate?
Sam: They reflect the lower and higher estimates of salt’s effect on blood pressure. Separately, the authors use repeated simulations to assess uncertainty in risk relationships. The headline range isn’t simply a confidence interval around an observed national result.
Alex: And is the benefit concentrated among people who already have the highest risk?
Sam: Every modeled adult group benefits, but not equally. Black adults have greater projected relative benefits, partly because hypertension is more prevalent. Women benefit particularly through stroke reduction, while older adults gain substantially through fewer coronary events.
Alex: The document also highlights younger adults. Does that mean they have the most events prevented?
Sam: That isn’t the claim. Younger and middle-aged adults have substantial projected relative reductions in mortality. Relative changes and the number of events prevented are different measures; the age-group findings shouldn’t be collapsed into one ranking.
Alex: How does salt reduction compare with the interventions cardiovascular researchers already spend time evaluating?
Sam: In the same simulated population and time frame, its projected coronary benefits are comparable to several prevention strategies. Those include reduced tobacco exposure, reduced body mass among obese adults, and expanded use of statins, medicines that lower cholesterol. The authors project greater stroke prevention from salt reduction than from those comparisons.
Alex: But that’s a comparison of modeled scenarios, not evidence that salt policy outperformed a smoking intervention in practice.
Sam: Yes, these are matched simulations, not a head-to-head trial. The useful comparison is the potential scale of benefit under the specified assumptions. It doesn’t show that implementing each strategy would be equally easy or successful.
Alex: Let’s turn to costs. What does the model actually count as a worthwhile investment?
Sam: The main scenario projects ten to twenty-four billion dollars in healthcare savings annually. The analysis also counts quality-adjusted life-years: survival weighted by quality of health. So its health measure goes beyond simply counting deaths prevented.
Alex: Those savings depend on what it costs to change the food supply. What implementation cost do they assume?
Sam: They use a World Health Organization estimate of one dollar per person annually for a national effort. But they exclude some costs, including those borne by industry to reformulate processed foods. That limits how comprehensively we should interpret the economic result.
Alex: Does the conclusion require hitting the full reduction immediately? National policies rarely work that cleanly.
Sam: No. Even a one-gram daily reduction, phased in over the modeled decade, is projected to save costs. Salt reduction also compares favorably with medicating everyone with hypertension. Medication produces more quality-adjusted life-years in that comparison, but adds costs rather than saving them.
Alex: What’s the main scientific reason those projected benefits could be smaller than advertised?
Sam: The model assumes cardiovascular benefits follow from the reduction in blood pressure. But pressure lowered through an intervention might not carry the same risk as naturally lower pressure. The authors test that possibility, and the projected benefit shrinks.
Alex: So the uncertainty isn’t only how far blood pressure falls. It’s also how faithfully that fall predicts later disease.
Sam: That’s the central bridge to scrutinize. Other sensitivity analyses change the assumed responses by age and race without overturning the main findings. The model also omits some possible benefits, but those omissions don’t establish that the estimates are necessarily conservative overall.
Alex: Who should read the full document, and where should they begin?
Sam: Researchers in cardiovascular prevention, nutrition policy, health disparities, and health economics should read it. Start with “Modeling approach and underlying assumptions,” then “Sensitivity analyses.” For policy decisions, read “Cost-Effectiveness” alongside the discussion of excluded costs.
Alex: And what should everyone else carry away?
Sam: Small changes across a population can produce large projected health gains. Here, the case for reducing salt is substantial, but its precise size depends on the bridge from blood pressure to disease.
Alex: Thanks for listening.